BOSTON, Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- Galecto, Inc. ( NASDAQ: GLTO ) , a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and financial results for the quarter ended June 30, 2025.

BOSTON, May 08, 2025 ( GLOBE NEWSWIRE ) -- Galecto, Inc. ( NASDAQ: GLTO ) , a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and financial results for the quarter ended March 31, 2025.

BOSTON, March 19, 2025 ( GLOBE NEWSWIRE ) -- Galecto, Inc. ( NASDAQ: GLTO ) , a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced its operating and financial results for the quarter and year ended December 31, 2024.

Galecto (GLTO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

BOSTON, Oct. 15, 2024 ( GLOBE NEWSWIRE ) -- Galecto, Inc. ( NASDAQ: GLTO ) , a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced the appointment of Dr. Amy Wechsler to its Board of Directors.

Galecto Inc GLTO shares are trading lower by 27% to $8.50 during Monday's session. The company issued 62,594 shares of common stock and 160,562 of preferred convertible shares to Bridge Medicine as part of their acquisition for the rights to BRM-1420.

Galecto will focus on cancer and liver disease, leveraging existing clinical stage asset GB1211 Bolsters pipeline by obtaining global rights to BRM-1420, a novel dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of acute myeloid leukemia ( AML )

BOSTON, Oct. 07, 2024 ( GLOBE NEWSWIRE ) -- Galecto, Inc. ( NASDAQ: GLTO ) , a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that, following an intensive strategic review process, Galecto has determined to focus on ...

BOSTON, Aug. 28, 2024 ( GLOBE NEWSWIRE ) -- Galecto, Inc. ( NASDAQ: GLTO ) , a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that it will implement a 1-for-25 Reverse Stock Split of its common stock ( the "Reverse ...